Positions

Professor of Medicine in the School of Medicine

2021 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2013 School of Medicine

Education

M.D., Shanghai Second Medical University (China) 1991

1991 Shanghai Second Medical University (China)

Fellow, Duke University, School of Medicine, HEMATOLOGY, ONCOLOGY, CELLULAR THERPAY 2007 - 2010

2010 Duke University, School of Medicine

Clinical Trials

CARTITUDE-6 (Multiple Myeloma)

A Phase 2, Study to Evaluate Prophylactic Interventions on Talquetamab-related oral toxicity

Publications, Grants & Awards

• Grants (29)
• Academics Articles (87)
• Conference Pages (21)
• Book Sections (4)

Showing 1 - 5 of 29

A phase II safety and efficacy study of Selinexor in combination with bispecific antibody in patients with relapsed/refractory multiple myeloma

2025-2030Karyopharm Therapeutics

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplan

2024-2029Stitching European Myeloma Network

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458;anti-BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory Multiple Myeloma (LINKER-

2024-2029Regeneron Pharmaceuticals, Inc.

Targeting sphingosine kinase 2 to enhance CAR T-cell therapy efficacy in multiple myeloma

2025-2027Cancer Research Institute

A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity

2024-2027Janssen Research & Development, LLC

DCI Centers, Cancer Types & Labs

Hematologic Malignancies and Cellular Therapy

Offices & Contact

Hematologic Malignancies
Durham, NC
27710

Box 3961 Med Ctr
Durham, NC
27710